Roche (OTCMKTS:RHHBY) Raised to “Hold” at Zacks Research

Roche (OTCMKTS:RHHBY) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other analysts have also recently weighed in on the company. HSBC reissued a “buy” rating and set a $57.00 price target on shares of Roche in a report on Wednesday, December 10th. Jefferies Financial Group downgraded Roche from a “hold” rating to a “moderate sell” rating in a report on Monday, October 27th. JPMorgan Chase & Co. upgraded shares of Roche from an “underweight” rating to a “neutral” rating in a research note on Monday, December 8th. Morgan Stanley reiterated an “underweight” rating on shares of Roche in a research note on Tuesday, December 2nd. Finally, Hsbc Global Res raised shares of Roche from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd. Three investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.

Roche Stock Performance

Shares of RHHBY opened at $51.61 on Monday. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.80. Roche has a 52 week low of $34.75 and a 52 week high of $53.00. The firm’s 50-day simple moving average is $47.93 and its 200 day simple moving average is $43.65.

Hedge Funds Weigh In On Roche

Hedge funds and other institutional investors have recently made changes to their positions in the company. Confluence Investment Management LLC raised its position in Roche by 6.4% during the fourth quarter. Confluence Investment Management LLC now owns 18,649 shares of the company’s stock valued at $962,000 after purchasing an additional 1,123 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Roche by 22.9% during the fourth quarter. GAMMA Investing LLC now owns 23,235 shares of the company’s stock worth $1,198,000 after acquiring an additional 4,336 shares during the last quarter. Hancock Whitney Corp lifted its position in shares of Roche by 4.8% in the 3rd quarter. Hancock Whitney Corp now owns 24,488 shares of the company’s stock worth $1,024,000 after purchasing an additional 1,116 shares during the period. Verity Asset Management Inc. lifted its holdings in Roche by 20.9% in the third quarter. Verity Asset Management Inc. now owns 10,990 shares of the company’s stock valued at $459,000 after buying an additional 1,898 shares during the period. Finally, Douglass Winthrop Advisors LLC acquired a new position in shares of Roche in the 3rd quarter valued at about $201,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann?La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.